Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, are a mainstay of metastatic colorectal cancer (mCRC) treatment. However, a significant number of patients suffer from primary or acquired resistance. RAS mutations are negative predictors of clin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Kasper, Stefan, Reis, Henning, Ziegler, Sophie, Nothdurft, Silke, Mueller, Andre, Goetz, Moritz, Wiesweg, Marcel, Phasue, Jeannette, Ting, Saskia, Wieczorek, Sarah, Even, Anna, Worm, Karl, Pogorzelski, Michael, Breitenbuecher, Sandra, Meiler, Johannes, Paul, Andreas, Trarbach, Tanja, Schmid, Kurt Werner, Breitenbuecher, Frank, Schuler, Martin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542236/
https://ncbi.nlm.nih.gov/pubmed/28507280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17438
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi